Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 61,699 | 57,677 | 48,756 | 52,913 | 52,304 |
| Cost of Goods | 31,344 | 47,626 | 15,944 | 52,495 | 34,606 |
| Gross Profit | 30,355 | 10,051 | 32,812 | 418 | 17,698 |
| Operating Expenses | 89,192 | 76,016 | 88,642 | 80,254 | 83,240 |
| Operating Income | -58,493 | -65,339 | -54,886 | -79,341 | -64,936 |
| Interest Expense | 5,062 | 5,084 | 5,085 | 4,962 | 4,805 |
| Other Income | 1,134 | 561 | 427 | 1,265 | 161 |
| Pre-tax Income | -62,421 | -69,862 | -59,544 | -83,038 | -69,580 |
| Net Income Continuous | -62,421 | -69,862 | -59,544 | -83,038 | -69,580 |
| Net Income | $-62,421 | $-69,862 | $-59,544 | $-83,038 | $-69,580 |
| EPS Basic Total Ops | -0.35 | -0.40 | -0.34 | -0.51 | -0.45 |
| EPS Basic Continuous Ops | -0.35 | -0.39 | -0.34 | -0.51 | -0.45 |
| EPS Diluted Total Ops | -0.35 | -0.40 | -0.34 | -0.51 | -0.45 |
| EPS Diluted Continuous Ops | -0.35 | -0.39 | -0.34 | -0.51 | -0.45 |
| EBITDA(a) | $-49,065 | $-55,886 | $-45,402 | $-69,836 | $-55,423 |